iSpecimen Inc.(ISPC)Earnings, Financials & Key Ratios
ISPC•NASDAQ
$2.57
Price updated Jul 6, 2026
AboutiSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.Show more
- Revenue$2M-79.2%
- EBITDA-$7M+43.3%
- Net Income-$10M+16.1%
- EPS (Diluted)-91.20+87.0%
- Gross Margin1.25%-97.1%
- EBITDA Margin-375.69%-173.0%
- Operating Margin-465.42%-239.7%
- Net Margin-543.68%-304.2%
- ROE-327.77%-71.2%
ISPC Price & Volume
iSpecimen Inc. (ISPC) stock price & volume — 10-year historical chart
Loading chart...
iSpecimen Faces Existential Revenue And Liquidity Crisis
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Existential liquidity and solvency
Key Thesis Takeaways
- iSpecimen's transactional marketplace model appears to be in a state of terminal decline, evidenced by a revenue collapse from $2.6M in 2023Q4 to just $156.0K in 2026Q1.
- The company's inability to achieve operational scalability is highlighted by persistent negative operating margins, which reached -465.42% in the most recent quarter.
- Given the rapid erosion of the equity base to $814.0K and a precarious current ratio of 0.62, the firm faces significant solvency risks that threaten its long-term viability as a going concern.
Verdict Logic
the company's fundamental outlook is severely compromised by a 94% revenue decline over the last ten quarters and a precarious liquidity position reflected in a current ratio of 0.62.
ISPC Growth Metrics
iSpecimen Inc. (ISPC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-25.1%
3 Years-42.97%
TTM-87.25%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM51.08%
Return on Capital
10 Years-126.49%
5 Years-126.49%
3 Years-175.29%
Last Year-260.99%
Peers Comparison
Key metrics vs top competitors for iSpecimen Inc. (ISPC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.57 | $356.88K | -0.03 | -79.24% | -543.68% | -327.77% | — | |
| $1.13 | $178.67M | -4.52 | 3.63% | -2.62% | -13.97% | — | |
| $565.09 | $16.14B | 36.98 | 19.97% | 17.19% | 120.89% | — | |
| $27.79 | $1.36B | -111.16 | 16.97% | -10.52% | -2.91% | — | |
| $170.94 | $13.09B | 58.94 | -0.37% | 5.35% | 4.7% | — | |
| $231.43 | $11.15B | -79.53 | -0.85% | -4.59% | -5.66% | — |
Compare ISPC vs Peers
iSpecimen Inc. (ISPC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ISPC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ISPC Frequently Asked Questions
iSpecimen Inc. (ISPC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is iSpecimen Inc.'s revenue?
iSpecimen Inc. (ISPC) reported $1.0M in revenue for fiscal year 2025. This represents a 77% decrease from $4.4M in 2018.
How fast is iSpecimen Inc. growing?
iSpecimen Inc. (ISPC) saw revenue decline by 79.2% over the past year.
Is ISPC profitable?
iSpecimen Inc. (ISPC) reported a net loss of $11.1M for fiscal year 2025.
Dividend & Returns
What is ISPC's return on equity?
iSpecimen Inc. (ISPC) has a return on equity (ROE) of -327.8%. Negative ROE indicates the company is unprofitable.
What is iSpecimen Inc.'s free cash flow?
iSpecimen Inc. (ISPC) had negative free cash flow of $6.5M in fiscal year 2025, likely due to heavy capital investments.